Molecular mode of action and role of TP53 in the sensitivity to the novel epothilone sagopilone (ZK-EPO) in A549 non-small cell lung cancer cells.

Sagopilone, an optimized fully synthetic epothilone, is a microtubule-stabilizing compound that has shown high in vitro and in vivo activity against a broad range of human tumor models. We analyzed the differential mechanism of action of sagopilone in non-small cell lung cancer cell lines in vitro....

Full description

Bibliographic Details
Main Authors: Sebastian Winsel, Anette Sommer, Julia Eschenbrenner, Kevin Mittelstaedt, Ulrich Klar, Stefanie Hammer, Jens Hoffmann
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2011-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC3084814?pdf=render
id doaj-36b2e18a74804e5fbfb19062c4715921
record_format Article
spelling doaj-36b2e18a74804e5fbfb19062c47159212020-11-25T02:39:01ZengPublic Library of Science (PLoS)PLoS ONE1932-62032011-01-0164e1927310.1371/journal.pone.0019273Molecular mode of action and role of TP53 in the sensitivity to the novel epothilone sagopilone (ZK-EPO) in A549 non-small cell lung cancer cells.Sebastian WinselAnette SommerJulia EschenbrennerKevin MittelstaedtUlrich KlarStefanie HammerJens HoffmannSagopilone, an optimized fully synthetic epothilone, is a microtubule-stabilizing compound that has shown high in vitro and in vivo activity against a broad range of human tumor models. We analyzed the differential mechanism of action of sagopilone in non-small cell lung cancer cell lines in vitro. Sagopilone inhibited proliferation of non-small cell lung cancer cell lines at lower nanomolar concentration. The treatment with sagopilone caused strong disturbances of cellular cytoskeletal organization. Two concentration-dependent phenotypes were observed. At 2.5 nM sagopilone or 4 nM paclitaxel an aneuploid phenotype occur whereas a mitotic arrest phenotype was induced by 40 nM sagopilone or paclitaxel. Interestingly, treatment with 2.5 nM of sagopilone effectively inhibited cell proliferation, but--compared to high concentrations (40 nM)--only marginally induced apoptosis. Treatment with a high versus a low concentration of sagopilone or paclitaxel regulates a non-overlapping set of genes, indicating that both phenotypes substantially differ from each other. Genes involved in G2/M phase transition and the spindle assembly checkpoint, like Cyclin B1 and BUBR1 were upregulated by treatment with 40 nM sagopilone. Unexpectedly, also genes involved in DNA damage response were upregulated under that treatment. In contrast, treatment of A549 cells with a low concentration of sagopilone revealed an upregulation of direct transcriptional target genes of TP53, like CDKN1A, MDM2, GADD45A, FAS. Knockdown of TP53, which inhibited the transcriptional induction of TP53 target genes, led to a significant increase in apoptosis induction in A549 cells when treated with a low concentration of sagopilone. The results indicate that activation of TP53 and its downstream effectors like CDKN1A by low concentrations of sagopilone is responsible for the relative apoptosis resistance of A549 cells and might represent a mechanism of resistance to sagopilone.http://europepmc.org/articles/PMC3084814?pdf=render
collection DOAJ
language English
format Article
sources DOAJ
author Sebastian Winsel
Anette Sommer
Julia Eschenbrenner
Kevin Mittelstaedt
Ulrich Klar
Stefanie Hammer
Jens Hoffmann
spellingShingle Sebastian Winsel
Anette Sommer
Julia Eschenbrenner
Kevin Mittelstaedt
Ulrich Klar
Stefanie Hammer
Jens Hoffmann
Molecular mode of action and role of TP53 in the sensitivity to the novel epothilone sagopilone (ZK-EPO) in A549 non-small cell lung cancer cells.
PLoS ONE
author_facet Sebastian Winsel
Anette Sommer
Julia Eschenbrenner
Kevin Mittelstaedt
Ulrich Klar
Stefanie Hammer
Jens Hoffmann
author_sort Sebastian Winsel
title Molecular mode of action and role of TP53 in the sensitivity to the novel epothilone sagopilone (ZK-EPO) in A549 non-small cell lung cancer cells.
title_short Molecular mode of action and role of TP53 in the sensitivity to the novel epothilone sagopilone (ZK-EPO) in A549 non-small cell lung cancer cells.
title_full Molecular mode of action and role of TP53 in the sensitivity to the novel epothilone sagopilone (ZK-EPO) in A549 non-small cell lung cancer cells.
title_fullStr Molecular mode of action and role of TP53 in the sensitivity to the novel epothilone sagopilone (ZK-EPO) in A549 non-small cell lung cancer cells.
title_full_unstemmed Molecular mode of action and role of TP53 in the sensitivity to the novel epothilone sagopilone (ZK-EPO) in A549 non-small cell lung cancer cells.
title_sort molecular mode of action and role of tp53 in the sensitivity to the novel epothilone sagopilone (zk-epo) in a549 non-small cell lung cancer cells.
publisher Public Library of Science (PLoS)
series PLoS ONE
issn 1932-6203
publishDate 2011-01-01
description Sagopilone, an optimized fully synthetic epothilone, is a microtubule-stabilizing compound that has shown high in vitro and in vivo activity against a broad range of human tumor models. We analyzed the differential mechanism of action of sagopilone in non-small cell lung cancer cell lines in vitro. Sagopilone inhibited proliferation of non-small cell lung cancer cell lines at lower nanomolar concentration. The treatment with sagopilone caused strong disturbances of cellular cytoskeletal organization. Two concentration-dependent phenotypes were observed. At 2.5 nM sagopilone or 4 nM paclitaxel an aneuploid phenotype occur whereas a mitotic arrest phenotype was induced by 40 nM sagopilone or paclitaxel. Interestingly, treatment with 2.5 nM of sagopilone effectively inhibited cell proliferation, but--compared to high concentrations (40 nM)--only marginally induced apoptosis. Treatment with a high versus a low concentration of sagopilone or paclitaxel regulates a non-overlapping set of genes, indicating that both phenotypes substantially differ from each other. Genes involved in G2/M phase transition and the spindle assembly checkpoint, like Cyclin B1 and BUBR1 were upregulated by treatment with 40 nM sagopilone. Unexpectedly, also genes involved in DNA damage response were upregulated under that treatment. In contrast, treatment of A549 cells with a low concentration of sagopilone revealed an upregulation of direct transcriptional target genes of TP53, like CDKN1A, MDM2, GADD45A, FAS. Knockdown of TP53, which inhibited the transcriptional induction of TP53 target genes, led to a significant increase in apoptosis induction in A549 cells when treated with a low concentration of sagopilone. The results indicate that activation of TP53 and its downstream effectors like CDKN1A by low concentrations of sagopilone is responsible for the relative apoptosis resistance of A549 cells and might represent a mechanism of resistance to sagopilone.
url http://europepmc.org/articles/PMC3084814?pdf=render
work_keys_str_mv AT sebastianwinsel molecularmodeofactionandroleoftp53inthesensitivitytothenovelepothilonesagopilonezkepoina549nonsmallcelllungcancercells
AT anettesommer molecularmodeofactionandroleoftp53inthesensitivitytothenovelepothilonesagopilonezkepoina549nonsmallcelllungcancercells
AT juliaeschenbrenner molecularmodeofactionandroleoftp53inthesensitivitytothenovelepothilonesagopilonezkepoina549nonsmallcelllungcancercells
AT kevinmittelstaedt molecularmodeofactionandroleoftp53inthesensitivitytothenovelepothilonesagopilonezkepoina549nonsmallcelllungcancercells
AT ulrichklar molecularmodeofactionandroleoftp53inthesensitivitytothenovelepothilonesagopilonezkepoina549nonsmallcelllungcancercells
AT stefaniehammer molecularmodeofactionandroleoftp53inthesensitivitytothenovelepothilonesagopilonezkepoina549nonsmallcelllungcancercells
AT jenshoffmann molecularmodeofactionandroleoftp53inthesensitivitytothenovelepothilonesagopilonezkepoina549nonsmallcelllungcancercells
_version_ 1724788109952942080